Close

Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive

Go back to Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive

Amedisys (AMED) PT Cut to $47 at Mizuho Following Results

November 4, 2016 7:05 AM EDT

Mizuho Securities analyst Sheryl Skolnick reiterated a Neutral rating and lowered her price target on Amedisys (NASDAQ: AMED) to $47.00 following results.

Skolnick commented, "What the new team has done for AMED in a very short period of time seems close to a miracle... More

Amedisys (AMED) Taps Kindred Healthcare's Gerard as COO

November 4, 2016 6:33 AM EDT

Amedisys, Inc. (Nasdaq: AMED) announced that industry leader Christopher Gerard will join the Company as Chief Operating Officer (COO) on January 3, 2017. Daniel McCoy will remain in this role until January 3, 2017.

Gerard brings more than 20 years of home health and hospice experience to the Company. In his new role, Gerard will be responsible for the Amedisys home health, hospice and personal care operations.

Chris has built an impressive track record of strategic, operational and financial accomplishments over the past two decades, said Amedisys President and Chief Executive Officer Paul... More

Amedisys (AMED) Misses Q3 EPS by 8c

November 3, 2016 5:03 PM EDT

Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $361.6 million versus the consensus estimate of $361.08 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

... More